The influence of acute coronary syndrome on levels of clopidogrel active metabolite and platelet inhibition in patients with and without CYP2C19*2(681 G>A), *3(636 G>A) and ABCB1(C3435C> T) gene polymorphisms

INTRODUCTION: Although ticagrelor and prasugrel remain the standard antiplatelet treatments in acute coronary syndrome (ACS), numerous patients still present with indications for clopidogrel use. AIM: We aimed to assess the levels of clopidogrel active metabolite and to evaluate the effect of the dr...

Descripción completa

Detalles Bibliográficos
Autores principales: Wójcik, Tomasz, Karolko, Bożena, Wiśniewski, Jerzy, Mysiak, Andrzej, Ściborski, Krzysztof, Onisk, Grzegorz, Lebioda, Arleta, Jonkisz, Anna, Protasiewicz, Marcin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2021
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8356835/
https://www.ncbi.nlm.nih.gov/pubmed/34400920
http://dx.doi.org/10.5114/aic.2021.106894

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8356835/
https://www.ncbi.nlm.nih.gov/pubmed/34400920
http://dx.doi.org/10.5114/aic.2021.106894

Ejemplares similares